Deciphera Pharmaceuticals Inc logo

Deciphera Pharmaceuticals Inc

$ 12.73 +0.27 (+2.17%) 08:08 PM EST
At Loss
Market Cap:
$ 1.00B
Enterprise V:
$ 680.89M
Avg Vol (2M):
Also Trade In:
Market Cap $:
PE Ratio:
At Loss
Avg Vol (2M):
Enterprise Value $:
PB Ratio:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for DCPH ( Deciphera Pharmaceuticals Inc ) from 2017 to Sep 27 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Deciphera Pharmaceuticals stock (DCPH) PE ratio as of Sep 27 2023 is 0. More Details

Deciphera Pharmaceuticals Inc (DCPH) PE Ratio (TTM) Chart


Deciphera Pharmaceuticals Inc (DCPH) PE Ratio (TTM) Historical Data

Total 1258
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Deciphera Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2023-09-28 At Loss 2023-07-25 At Loss
2023-09-26 At Loss 2023-07-24 At Loss
2023-09-25 At Loss 2023-07-21 At Loss
2023-09-22 At Loss 2023-07-20 At Loss
2023-09-21 At Loss 2023-07-19 At Loss
2023-09-20 At Loss 2023-07-18 At Loss
2023-09-19 At Loss 2023-07-17 At Loss
2023-09-18 At Loss 2023-07-14 At Loss
2023-09-15 At Loss 2023-07-13 At Loss
2023-09-14 At Loss 2023-07-12 At Loss
2023-09-13 At Loss 2023-07-11 At Loss
2023-09-12 At Loss 2023-07-10 At Loss
2023-09-11 At Loss 2023-07-07 At Loss
2023-09-08 At Loss 2023-07-06 At Loss
2023-09-07 At Loss 2023-07-05 At Loss
2023-09-06 At Loss 2023-07-03 At Loss
2023-09-05 At Loss 2023-06-30 At Loss
2023-09-01 At Loss 2023-06-29 At Loss
2023-08-31 At Loss 2023-06-28 At Loss
2023-08-30 At Loss 2023-06-27 At Loss
2023-08-29 At Loss 2023-06-26 At Loss
2023-08-28 At Loss 2023-06-23 At Loss
2023-08-25 At Loss 2023-06-22 At Loss
2023-08-24 At Loss 2023-06-21 At Loss
2023-08-23 At Loss 2023-06-20 At Loss
2023-08-22 At Loss 2023-06-16 At Loss
2023-08-21 At Loss 2023-06-15 At Loss
2023-08-18 At Loss 2023-06-14 At Loss
2023-08-17 At Loss 2023-06-13 At Loss
2023-08-16 At Loss 2023-06-12 At Loss
2023-08-15 At Loss 2023-06-09 At Loss
2023-08-14 At Loss 2023-06-08 At Loss
2023-08-11 At Loss 2023-06-07 At Loss
2023-08-10 At Loss 2023-06-06 At Loss
2023-08-09 At Loss 2023-06-05 At Loss
2023-08-08 At Loss 2023-06-02 At Loss
2023-08-07 At Loss 2023-06-01 At Loss
2023-08-04 At Loss 2023-05-31 At Loss
2023-08-03 At Loss 2023-05-30 At Loss
2023-08-02 At Loss 2023-05-26 At Loss
2023-08-01 At Loss 2023-05-25 At Loss
2023-07-31 At Loss 2023-05-24 At Loss
2023-07-28 At Loss 2023-05-23 At Loss
2023-07-27 At Loss 2023-05-22 At Loss
2023-07-26 At Loss 2023-05-19 At Loss

Deciphera Pharmaceuticals Inc (DCPH) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.